A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
Latest Information Update: 03 May 2022
At a glance
- Drugs Alemtuzumab (Primary) ; Interleukin-15 (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell prolymphocytic leukaemia
- Focus Adverse reactions
- 16 Jun 2021 Status changed from active, no longer recruiting to completed.
- 03 Jun 2021 Planned End Date changed from 31 Jan 2025 to 31 Dec 2021.
- 03 Jun 2021 Planned primary completion date changed from 31 Jan 2023 to 31 Dec 2021.